Notice of Intent to Reissue PAR-18-847 “Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01- Clinical Trial Optional)” and PAR-18-848 (R21 - Clinical Trial Optional) as a Notice of Special Interest (NOSI)
Notice Number:
NOT-OD-21-114

Key Dates

Release Date:

April 23, 2021

Related Announcements

PAR-18-847 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 - Clinical Trial Optional) 

PAR-18-848 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 - Clinical Trial Optional)

Issued by

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute on Minority Health and Health Disparities (NIMHD)

National Cancer Institute (NCI)

Purpose

This Notice is to inform the research community that the Office of Disease Prevention and participating NIH Institutes, Centers, and Offices intend to reissue the Funding Opportunity Announcement (FOA) PAR-18-847 "Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 - Clinical Trial Optional)" and PAR-18-848 "Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 - Clinical Trial Optional)."

When reissued, these FOAs will utilize the Notice of Special Interest (NOSI) mechanism. Modifications to this FOA will be the inclusion of new and revised research priorities. This Notice is being published now to inform prospective applicants in advance of this action. The NOSI is expected to be published in June 2021.

Research Initiative

The purpose of the forthcoming  NOSI is to communicate our interest in research on electronic nicotine delivery systems (ENDS). Research on alternative nicotine and tobacco delivery systems [e.g.,heated tobacco products (also called heat-not-burn)] will also be considered. Studies should examine population-based, clinical, and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive.

Inquiries

Please direct all inquiries to:

Melissa C. Green Parker, PhD
Office of Disease Prevention (ODP)
Telephone: 301-480-1161
Email: melissa.greenparker@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices